drugset / Trial / NCT07056309
A Study of Remternetug (LY3372993) in Healthy Participants
RandomizedParallel-groupOpen-labelBasic science
Summary
The main purpose of this study is to evaluate to different formulations of remternetug after single subcutaneous (SC) administration with either an autoinjector (AI) or a prefilled syringe (PFS). The study will look at the amount of remternetug that gets into the bloodstream and how long it takes the body to get rid of the remternetug when given as two different formulations. Participation in the study will last approximately 155 days.
Timeline
- Start
- 2025-06-24
- Primary completion
- 2025-12-15
- Completion
- 2025-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remternetug | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.